Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
Top Cited Papers
Open Access
- 10 January 2026
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (6) , 778-794
Abstract
Background: The role of statins in cirrhosis remains controversial. Historically restricted due to safety concerns, emerging evidence highlights potential pleiotropic benefits, though effects on mortality and decompensation remain uncertain. Aims: To evaluate the effects of statin therapy on all‐cause mortality, hepatic decompensation, hepatic venous pressure gradient (HVPG), and hepatocellular carcinoma (HCC) in cirrhosis. Methods: We systematically searched major databases until July 2025 for randomised controlled trials (RCTs) and observational studies comparing statin therapy versus non‐use in cirrhosis. Random‐effects meta‐analyses were performed. Results: The meta‐analysis included 25 studies (9 RCTs, 16 observational) with 81,992 patients. Statins reduced all‐cause mortality in the overall analysis (unadjusted odds ratio 0.59; 95% CI: 0.48–0.71) and in RCTs (odds ratio 0.45; 95% CI 0.25–0.82), supported by a significant HVPG reduction. Conversely, statins reduced hepatic decompensation in the overall analysis (unadjusted odds ratio 0.56; 95% CI: 0.47–0.66) but not in RCTs (odds ratio 0.75; 95% CI: 0.52–1.09). Observational data indicated a protective association for HCC (adjusted hazard ratio 0.61; 95% CI: 0.46–0.82), and no RCT reported this outcome. Conclusions: Statin therapy is associated with improved survival in cirrhosis, supported mechanistically by reductions in portal pressure. Observational evidence suggests benefits for decompensation and HCC, though these remain uncertain due to residual confounding. Large‐scale, long‐term RCTs are needed to clarify the role of statins as disease‐modifying therapy in cirrhosis.Keywords
This publication has 55 references indexed in Scilit:
- Statin Use and Risk of Hepatocellular Carcinoma and Liver Fibrosis in Chronic Liver DiseaseJAMA Internal Medicine, 2025
- Statin Therapy is Associated With Lower Risk of Mortality Among Liver Transplant Candidates With Metabolic Dysfunction-associated SteatohepatitisJournal of Clinical and Experimental Hepatology, 2024
- Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter VariantHepatology Communications, 2021
- Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis BHepatology, 2019
- Cochrane Handbook for Systematic Reviews of Interventions2019
- EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosisJournal of Hepatology, 2018
- Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluationLiver Transplantation, 2018
- Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2017
- Statins decrease the risk of decompensation in hepatitis B virus– and hepatitis C virus–related cirrhosis: A population‐based studyHepatology, 2017
- Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trialDigestive and Liver Disease, 2015